BioLamina

• 12/09/2023
• Unknown
• $18,216,000

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality.

BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality.

BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

---

---